---
title: "monumental-1"
date: "2024-08-24"
tags:
  - building
---

> [!NOTE]
> ğŸŒ± created from: [[bite_rrmm]]

# monumental-1

- Design: Phase 1 study
- Number of patients: 232
- Patients characteristics: Heavily pretreated relapsed or refractory multiple myeloma patients
- Agent: Talquetamab, administered intravenously or subcutaneously in doses ranging from 0.5 to 180 Î¼g per kilogram of body weight
- Treatment line: Patients who had received a median of six previous lines of therapy
- Trial Acronym: MonumenTAL-1, ClinicalTrials.gov number NCT03399799

| Parameter                   | Result                                                |
| --------------------------- | ----------------------------------------------------- |
| Response rate               | 70% at 405 Î¼g dose, 64% at 800 Î¼g dose                |
| Median duration of response | 10.2 months at 405 Î¼g dose, 7.8 months at 800 Î¼g dose |

- Highlight of toxicity: Common adverse events included cytokine release syndrome, skin-related events, and dysgeusia, primarily low-grade.
  - skin, nail, tounge
  - å‘³è¦ºéšœç¤™ï¼ˆè‹±èªï¼šDysgeusiaï¼‰æŒ‡çš„æ˜¯å‘³è¦ºçš„æ‰­æ›²æˆ–å¤±çœŸã€‚å‘³è¦ºéšœç¤™é€šå¸¸èˆ‡å–ªå¤±å‘³è¦ºã€å‘³è¦ºé²éˆæœ‰é—œã€‚å‘³è¦ºéšœç¤™å¯èƒ½æ˜¯æŸå€‹ç–¾ç—…çš„ä¸»è¦ç—‡ç‹€æˆ–æ¬¡è¦ç—‡ç‹€ã€‚
- One line summary: Talquetamab showed significant response in heavily pretreated relapsed or refractory multiple myeloma patients with manageable toxicity.
